Can endocan serve as a molecular "hepatostat" in liver regeneration?
Endocan
Hepatectomy
Liver transplantation
Regeneration
eEF2K
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
27 02 2023
27 02 2023
Historique:
received:
26
09
2022
accepted:
13
02
2023
entrez:
28
2
2023
pubmed:
1
3
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Intriguingly, liver regeneration after injury does not induce uncontrolled growth and the underlying mechanisms of such a "hepatostat" are still not clear. Endocan, a proteoglycan, was implicated in liver regeneration. It can support the function of hepatocyte growth factor/scatter factor in tissue repair after injury. Endostatin, a 20 kDa C-terminal fragment of collagen XVIII, may modulate the cessation of liver regeneration. eEF2K, a protein kinase that regulates protein synthesis, can regulate angiogenesis. Thus, we investigated the role of endocan, endostatin and eEF2K during normal liver regeneration. Serum samples and regenerating remnant liver tissues were obtained on various days after partial hepatectomy in rats. mRNA expression levels of Vegf and Pcna were analyzed in addition to immunohistochemical evaluations. Liver tissue protein levels of endostatin, endocan and p-eEF2K/eEF2K were determined with Western blot. Serum levels of endostatin and endocan were assessed with ELISA. Pcna expression level in residual liver tissues peaked on day-1, while Vegf expression reached its highest level on days 1-3 after partial hepatectomy (70%). Endocan activity declined gradually on days 1-7. The decrease in liver endocan expression was accompanied by an increase in serum endocan levels. Partial hepatectomy induced a rapid increase in liver endostatin levels. Following its surge on day-1, endostatin expression gradually declined, which was accompanied by a peak in serum endostatin. Finally, partial hepatectomy was shown to regulate eEF2K; thus, increasing protein translation. We revealed possible mechanistic insights into liver regeneration by examining the associations of Pcna, Vegf, endocan, endostatin, eEF2K with hepatic regeneration after partial hepatectomy. Indeed, endocan might serve as a useful biomarker to monitor clinical prognosis in a plethora of conditions such as recovery of donor's remaining liver after living-donor liver transplant. Whether endocan might represent a strategy to optimize liver regeneration when given therapeutically needs to be investigated in future studies.
Sections du résumé
BACKGROUND
Intriguingly, liver regeneration after injury does not induce uncontrolled growth and the underlying mechanisms of such a "hepatostat" are still not clear. Endocan, a proteoglycan, was implicated in liver regeneration. It can support the function of hepatocyte growth factor/scatter factor in tissue repair after injury. Endostatin, a 20 kDa C-terminal fragment of collagen XVIII, may modulate the cessation of liver regeneration. eEF2K, a protein kinase that regulates protein synthesis, can regulate angiogenesis. Thus, we investigated the role of endocan, endostatin and eEF2K during normal liver regeneration.
METHODS
Serum samples and regenerating remnant liver tissues were obtained on various days after partial hepatectomy in rats. mRNA expression levels of Vegf and Pcna were analyzed in addition to immunohistochemical evaluations. Liver tissue protein levels of endostatin, endocan and p-eEF2K/eEF2K were determined with Western blot. Serum levels of endostatin and endocan were assessed with ELISA.
RESULTS
Pcna expression level in residual liver tissues peaked on day-1, while Vegf expression reached its highest level on days 1-3 after partial hepatectomy (70%). Endocan activity declined gradually on days 1-7. The decrease in liver endocan expression was accompanied by an increase in serum endocan levels. Partial hepatectomy induced a rapid increase in liver endostatin levels. Following its surge on day-1, endostatin expression gradually declined, which was accompanied by a peak in serum endostatin. Finally, partial hepatectomy was shown to regulate eEF2K; thus, increasing protein translation.
CONCLUSIONS
We revealed possible mechanistic insights into liver regeneration by examining the associations of Pcna, Vegf, endocan, endostatin, eEF2K with hepatic regeneration after partial hepatectomy. Indeed, endocan might serve as a useful biomarker to monitor clinical prognosis in a plethora of conditions such as recovery of donor's remaining liver after living-donor liver transplant. Whether endocan might represent a strategy to optimize liver regeneration when given therapeutically needs to be investigated in future studies.
Identifiants
pubmed: 36849916
doi: 10.1186/s10020-023-00622-9
pii: 10.1186/s10020-023-00622-9
pmc: PMC9972723
doi:
Substances chimiques
Proliferating Cell Nuclear Antigen
0
Endostatins
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Informations de copyright
© 2023. The Author(s).
Références
Cell Biochem Funct. 2020 Aug;38(6):817-825
pubmed: 32515027
Glia. 2005 Dec;52(4):309-24
pubmed: 16078232
Liver Int. 2019 May;39(5):788-801
pubmed: 30843314
Br J Pharmacol. 2003 Oct;140(4):595-610
pubmed: 14504135
J Neuropathol Exp Neurol. 2009 Jun;68(6):633-41
pubmed: 19458546
Int J Mol Sci. 2021 Feb 27;22(5):
pubmed: 33673713
Cancer Res. 2013 Feb 1;73(3):1097-106
pubmed: 23243026
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Can J Gastroenterol Hepatol. 2015 Nov-Dec;29(8):427-30
pubmed: 26669300
Int J Cell Biol. 2013;2013:705027
pubmed: 23606845
Science. 2021 Feb 26;371(6532):
pubmed: 33632817
Cell. 1997 Jan 24;88(2):277-85
pubmed: 9008168
Experientia. 1993 May 15;49(5):447-55
pubmed: 8500599
Nat Rev Mol Cell Biol. 2021 Sep;22(9):608-624
pubmed: 34079104
Front Cardiovasc Med. 2022 Jan 05;8:798699
pubmed: 35071362
Atherosclerosis. 2015 Nov;243(1):339-43
pubmed: 26448266
Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4023-34
pubmed: 15505052
J Neurooncol. 2014 May;117(3):485-91
pubmed: 24504498
J Hepatol. 2011 Oct;55(4):936-8
pubmed: 21708198
Surgery. 2010 Feb;147(2):288-94
pubmed: 20004434
World J Gastroenterol. 2005 Dec 14;11(46):7254-60
pubmed: 16437624
Acta Pharmacol Sin. 2016 Mar;37(3):285-94
pubmed: 26806303
J Proteome Res. 2020 Jan 3;19(1):174-185
pubmed: 31802674
Science. 2003 Feb 7;299(5608):890-3
pubmed: 12574630
J Surg Res. 2007 Dec;143(2):337-43
pubmed: 17574579
Science. 1997 Apr 4;276(5309):60-6
pubmed: 9082986
Int J Cancer. 2020 Mar 1;146(5):1383-1395
pubmed: 31286509
EMBO Mol Med. 2010 Aug;2(8):294-305
pubmed: 20652897
J Histochem Cytochem. 2001 Jan;49(1):121-30
pubmed: 11118484
Nat Clin Pract Nephrol. 2007 Mar;3(3):164-70
pubmed: 17322928
Cells. 2019 Sep 23;8(10):
pubmed: 31547621
Front Mol Biosci. 2021 Aug 31;8:727863
pubmed: 34532346
Am J Pathol. 2010 Jan;176(1):2-13
pubmed: 20019184
Expert Rev Gastroenterol Hepatol. 2014 Nov;8(8):897-907
pubmed: 24964729
Mediators Inflamm. 2020 Apr 01;2020:3534042
pubmed: 32317862
Exp Cell Res. 2007 Apr 15;313(7):1285-94
pubmed: 17362927
Mol Cancer. 2007 Aug 07;6:50
pubmed: 17683638
J Int Med Res. 2010 Mar-Apr;38(2):498-510
pubmed: 20515564
Br J Pharmacol. 2007 Sep;152(1):9-20
pubmed: 17549047
Int J Mol Sci. 2021 Jul 30;22(15):
pubmed: 34360975
J Clin Invest. 2010 Nov;120(11):4129-40
pubmed: 20978355
J Cell Physiol. 2007 Nov;213(2):286-300
pubmed: 17559071
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Horm Mol Biol Clin Investig. 2018 Nov 21;41(1):
pubmed: 30462610
Cell Mol Immunol. 2020 Jul;17(7):753-764
pubmed: 31481754
J Biol Chem. 2016 Sep 9;291(37):19545-57
pubmed: 27466362
Cell Signal. 2017 Aug;36:212-221
pubmed: 28502587
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):930-939
pubmed: 29450540
Bioinformatics. 2007 Jul 15;23(14):1846-7
pubmed: 17496320
Am J Physiol Endocrinol Metab. 2009 Jun;296(6):E1262-8
pubmed: 19240255
J Pathol. 2012 Nov;228(3):378-90
pubmed: 22786655
New Biol. 1990 Oct;2(10):843-50
pubmed: 1964087
J Biol Chem. 1996 Aug 23;271(34):20458-64
pubmed: 8702785
Hepatogastroenterology. 2001 Mar-Apr;48(38):556-62
pubmed: 11379353
J Immunol. 2001 Sep 15;167(6):3099-106
pubmed: 11544294
Urology. 2012 Sep;80(3):738.e1-8
pubmed: 22608803
J Clin Invest. 2013 Jan;123(1):164-78
pubmed: 23202732
Surg Today. 2011 Dec;41(12):1622-9
pubmed: 21969195
J Med Biochem. 2020 Sep 02;39(3):363-371
pubmed: 33269025
J Surg Res. 2004 Apr;117(2):306-15
pubmed: 15047136
Nature. 2010 Nov 11;468(7321):310-5
pubmed: 21068842
J Biol Chem. 2001 Dec 21;276(51):48341-9
pubmed: 11590178
Science. 2021 Feb 26;371(6532):
pubmed: 33632818
Front Immunol. 2022 Jun 23;13:886822
pubmed: 35812393
Database (Oxford). 2018 Jan 1;2018:
pubmed: 30403794
Lab Anim. 2015 Apr;49(1 Suppl):81-8
pubmed: 25835741
Cancer. 2016 Apr 15;122(8):1216-27
pubmed: 26914713
Nephrol Dial Transplant. 2004 Jul;19 Suppl 4:iv6-10
pubmed: 15240842